How Drug Promotion Might Change Under Trump's Rx Pricing Plan
DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.
You may also be interested in...
HHS lacks authority to require drug price disclosures in TV ads, judge rules. Even if legislation were to explicitly give the Trump Administration such authority, First Amendment issues would still linger.
With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.